louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00149656: The Effects of Nutritional Supplementation and Drug Abuse on HIV
Official title: HIV Disease, Drug Abuse, and Nutrient Therapy in Botswana
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Substance-Related Disorders
Keywords: Treatment Naive
Multivitamins
Selenium
Supplementation
HIV Disease Progression
Lead sponsor: Florida International University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2005-09-08
Enrollment: 878
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to determine whether supplementation with multivitamins and selenium will delay disease progression in HIV infected individuals in Botswana. The study will also assess how drug abuse modifies the effect of nutritional supplementation on HIV disease progression.

Detailed description: Botswana has the highest rates of HIV infection in the world. In addition, drug abuse has become an emerging problem in Botswana. Past research suggests that multivitamin and selenium supplementation slows the progression of HIV disease. The purpose of this trial is to evaluate the effectiveness of supplementation with multivitamins and selenium in HIV infected individuals in Botswana.

This trial will last 2 years. Participants will be randomly assigned to 4 groups: a combination of multivitamins with selenium, multivitamins alone, selenium alone, or placebo.

Eligibility criteria: Inclusion Criteria:

* HIV infected
* CD4 count greater than 350 cells/mm3
* Identified from the Infectious Disease Care Clinic
* Body mass index greater than 18 for women and greater than 18.5 for men

Exclusion Criteria:

* Current AIDS-defining condition
* Currently participating in another clinical trial
* Pregnant or intends to become pregnant during the study

Primary outcomes:
measure: HIV Disease Progression
timeFrame: For at least 6 months
Secondary outcomes:
measure: Morbidity
timeFrame: For at least 6 months
Other outcomes:
Locations:
city: Gaborone
country: Botswana
facility: Princess Marina Hospital
Study officials:
affiliation: Florida International University
name: Marianna K. Baum, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02381756: Ultrasound and Left Ventricular Systolic Function
Official title: Ultrasound Evaluation of the Left Ventricular Systolic Function in Intensive Care Unit.
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Dysfunction, Left Ventricular
Lead sponsor: Fondation Ophtalmologique Adolphe de Rothschild
Sponsor class: NETWORK
First posted: 2015-03-06
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: ICU patients intubated and ventilated

Brief summary: The aim of this study is to evaluate, in an intensive care unit, the reproducibility between two non-cardiologists operators and a cardiologist expert in echocardiogram, of the Simpson method and of the calculation of GLS for the evaluation of the systolic function of the left ventricle in critically ill patients intubated and ventilated.


Eligibility criteria: Inclusion Criteria:

* ICU patients intubated and ventilated

Exclusion Criteria:

* Arrhythmia or variability of heart rate
* Technical impossibility to perform the ultrasound exam
* Known pregnancy or lactation
* Non-affiliation to a social security scheme (beneficiary or assignee)
* Patient under legal protection
* Patient refusal to participate

Primary outcomes:
measure: Reproducibility of measurements of the ejection fraction of the left ventricle by two measurement methods and reproducibility of myocardial strain measurements between operators
timeFrame: Baseline
Secondary outcomes:
measure: Area under the ROC curve of the value of myocardial strain (GLS)
timeFrame: Baseline
Other outcomes:
Locations:
city: Paris
country: France
facility: Fondation Ophtalmologique Adolphe de Rothschild
state: Ile De France
Study officials:
affiliation: Fondation Ophtalmologique Adolphe de Rothschild
name: Nadia Benyounes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05766956: Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Pragmatic Clinical Trial
Official title: Effect of Advanced Care at Home vs. Traditional Brick-and-Mortar Hospital Care in Acutely Ill Adults: A Pragmatic Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Illness
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2023-03-13
Enrollment: 1150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The purpose of this study is to compare two care delivery models that are currently being implemented in routine practice settings. The findings from this study will inform future clinical decision making, such as which patients might be more suited for which care delivery model.


Eligibility criteria: Inclusion Criteria:

* Adult patients, 18 years of age and older
* Present to one of the participating hospitals
* Have a chief complaint of one of the target diagnoses
* Are within a certain geographical area (based on zip codes)
* Have a health insurance plan that covers ACH services
* Have the capacity to consent or could assent with the consent of a health care proxy who is physically present

Exclusion Criteria:

* Not suitable for ACH or inpatient hospital care as determined by the patient's clinical team
* Do not have the capacity to consent or assent with the assistance of a health care proxy

Primary outcomes:
measure: The primary outcome is a composite outcome of all-cause mortality
timeFrame: 30 days post-discharge
measure: 30-day readmission
timeFrame: 30 days post-discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Arizona
state: Arizona
city: Jacksonville
country: United States
facility: Mayo Clinic Jacksonville
state: Florida
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Eau Claire
country: United States
facility: Mayo Clinic Health System
state: Wisconsin
Study officials:
References:
Clinical trial NCT00867256: Cormet Large Diameter Metal on Metal (LDMOM) Total Hip System (G030265)
Official title: Large Diameter Metal-on-Metal Total Hip System IDE
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Osteoarthritis
Rheumatoid Arthritis
Avascular Necrosis
Keywords: arthritis
Lead sponsor: Corin
Sponsor class: INDUSTRY
First posted: 2009-03-23
Enrollment: 195
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To demonstrate the safety and efficacy of the Cormet Large Diameter Metal on Metal (LDMOM) Total Hip System using a composite clinical success (CCS) primary endpoint.

Detailed description: The results from the Cormet Large Diameter Metal on Metal (LDMOM) Total Hip System cohort will be compared to the historical results from a ceramic on ceramic (CoC) hip system cohort. The primary endpoint clinical composite success (CCS) criterion at 24 months postoperative is based on a Harris Hip Score ≥ 80 and the absence of any revision,replacement, or modification of any study component.

Eligibility criteria: INCLUSION CRITERIA:

Patient:

* is skeletally mature
* is mentally capable of completing follow-up forms
* will be available for follow-up out to 2 years
* has a preoperative Harris Hip Score \<70 points
* has been deemed a candidate for hip replacement by diagnosis of the investigator.

EXCLUSION CRITERIA:

Patient:

* has active joint infection
* has had previous hip arthrodesis (fusion)
* has had above knee amputation of either extremity
* has active neoplastic disease
* has a need for a structural bone graft in the operative side
* has an ipsilateral hemi or total arthroplasty of any kind
* has a nonunion or malunion of any part of the femur on operative side
* has severe osteoporosis of the pelvis and/or femur as noted on standard radiograph
* is a prisoner
* is pregnant
* is known to be allergic to implant materials
* is morbidly obese.

Primary outcomes:
measure: Composite clinical criterion
timeFrame: 24-months postoperative
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Corin Ltd
name: Giulia Carli
role: STUDY_DIRECTOR
References:
Clinical trial NCT01623856: Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients
Official title: Observational - Candidate Gene Variants and Childhood/Adolescent Non-Hodgkin Lymphoma: A Preliminary Investigation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Childhood Burkitt Lymphoma
Childhood Lymphoblastic Lymphoma
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2012-06-20
Enrollment: 483
Sex: ALL
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with lymphoblastic lymphoma (LL) or Burkitt lymphoma ( BL) enrolled on the Children Oncology Group (COG) protocols 5961, A5971, or ANHL01P1.

Brief summary: This research studies genes associated with non-Hodgkin lymphoma in young patients. Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer

Detailed description: OBJECTIVES:

I. To conduct a preliminary investigation of the effects of loci strongly and consistently associated in prior genome-wide association studies (GWAS) and validation studies of childhood/adolescent acute lymphoblastic leukemia (ALL), adult non-Hodgkin lymphoma (NHL), autoimmune diseases, and atopic diseases on the risk of NHL (lymphoblastic and Burkitt lymphomas) in children and adolescents.

OUTLINE:

DNA samples are analyzed by single nucleotide polymorphism and genotyped by fluorogenic polymerase chain reaction (PCR)-based allelic discrimination (Taqman) assays using the ABI Prism 7900HT reverse transcriptase (RT)-PCR system.

Eligibility criteria: Inclusion Criteria:

* Slides and/or other available specimens from patients diagnosed with lymphoblastic lymphoma (LL) or Burkitt lymphoma ( BL) enrolled on the Children Oncology Group (COG) protocols 5961, A5971, and ANHL01P1 collected at the time of diagnosis and currently housed at the Biopathology Center at Nationwide Children's Hospital

  * Samples from non-Hispanic white patients
* DNA samples from 384 healthy, anonymous, non-Hispanic white blood donors used as controls
* See Disease Characteristics
* Not specified

Primary outcomes:
measure: Potential deviations from Hardy-Weinberg Equilibrium (HWE)
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Monrovia
country: United States
facility: Children's Oncology Group
state: California
Study officials:
affiliation: Children's Oncology Group
name: Amy Linabery, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04750356: SARS-CoV-2 (COVID-19) Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study)
Official title: SARS-CoV-2 Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: SARS-CoV Infection
Lead sponsor: University College, London
Sponsor class: OTHER
Collaborators: name: Francis Crick Institute
First posted: 2021-02-11
Enrollment: 6000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals who have previously provided samples for SARS-CoV-2 testing at the Crick COVID 19 Consortium Testing centre

Brief summary: The study aims to investigate SARS-CoV-2 susceptibility, transmission and disease severity in healthcare workers and patients.

Residual specimens from an existing collection of samples in viral inactivating buffer and derivatives and serum from the Crick COVID-19 Consortium Testing centre (Cohort A1) and additional biological material collected prospectively (Cohorts A2 and B) will be used for research into SARS-CoV-2 transmission, evolution and immune control. This testing centre is a partnership between UCLH and The Francis Crick Institute to provide COVID 19 RT PCR testing for healthcare workers (HCWs) and patients in London Hospitals and care homes. A third group (Cohort C) of the study will allow for collaborative work with other REC approved research studies that have used the Crick COVID-19 Consortium Testing centre and will involve the use of study samples already collected from each study to be analysed under the SARS-CoV-2 Longitudinal Study end points


Eligibility criteria: Inclusion Criteria:

* Individuals who have previously provided nasal throat swab samples for SARS-CoV-2 testing at the Crick COVID 19 Consortium Testing centre.
* ≥18 years of age
* To enrol in the SARS-CoV-2 positive cohort of the study, the participant should have a positive RT qPCR result
* Employees based at the participating sites including who had their serology and/or swab tested (for recruitment to Cohort B)
* Participants enrolled in other studies who had their samples processed by using the Crick COVID 19 Consortium Testing centre (for recruitment to Cohort C).
* Written informed consent (except Cohort A1)

Primary outcomes:
measure: SARS-CoV-2 susceptibility in healthcare workers and patients
timeFrame: 24 months
measure: SARS-CoV-2 transmission in healthcare workers and patients
timeFrame: 24 months
measure: SARS-CoV-2 severity in healthcare workers and patients
timeFrame: 24 months
measure: SARS-CoV-2 severity in healthcare workers and patients
timeFrame: 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: Ealing and Northwick Park hospital
city: London
country: United Kingdom
facility: The Francis Crick Institute
city: London
country: United Kingdom
facility: UCLH
Study officials:
References:
Clinical trial NCT00564356: The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment
Official title: The Safety of Cataract Removal by Phacoemulsification Surgery in Patients Under Anti-aggregant and Coumadin Treatment
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Efficacy
Complications
Keywords: cataract, phacoemulsification, coumadin, antiaggregants
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2007-11-27
Enrollment: 75
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification in patients on coumadin and antiaggregant treatments.

Design: Consecutive prospective study.

Detailed description: To assess the risks of intra- and postoperative bleeding tendency associated with cataract surgery by phacoemulsification technique in patients on coumadin and antiaggregant treatment Design: Consecutive prospective study.

Eligibility criteria: Inclusion Criteria:

* patients who give informed consent to participate in the study

Exclusion Criteria:

* single eye complicated cataract

Primary outcomes:
measure: safety and efficacy of cataract surgery with phacoemulsification under coumadin and antiaggregant treatment
timeFrame: 3.5 years
Secondary outcomes:
measure: other complications
timeFrame: 3.5 years
Other outcomes:
Locations:
city: Ramat-Gan
country: Israel
facility: Sheba Medical Center
Study officials:
affiliation: Sheba Medical Center
name: Ophira Salomon
role: STUDY_DIRECTOR
References:
citation: Barequet IS, Sachs D, Priel A, Wasserzug Y, Martinowitz U, Moisseiev J, Salomon O. Phacoemulsification of cataract in patients receiving Coumadin therapy: ocular and hematologic risk assessment. Am J Ophthalmol. 2007 Nov;144(5):719-723. doi: 10.1016/j.ajo.2007.07.029. Epub 2007 Sep 17.
Clinical trial NCT01161056: Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways
Official title: Genes and Phenotype (GAP) A National Resource for Genotype-Phenotype Studies of Immunological and Inflammatory Pathways
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Immune System Diseases
Lead sponsor: Northwell Health
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
name: University of Alabama at Birmingham
First posted: 2010-07-13
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy Controls

Brief summary: The purpose of this study is to enrol generally healthy adults, who are asked to provide a blood sample, to study how the immune system works.

Detailed description: The primary purpose of this research is to develop a better understanding of how the immune system works. By studying immune function in many people, we will be able to determine the range of normal variation.

The second purpose is to enroll people who are willing to serve as comparisons in future research studies into the Genotype and Phenotype Research Registry (GAP Registry).

Volunteers are asked to provide information on age, ethnicity and medical history. Volunteers are asked to provide a blood sample of up to 100cc and allow us to contact you about additional studies.

Eligibility criteria: Inclusion Criteria:

* Over age 18
* Generally healthy

Exclusion Criteria:

* History of autoimmune disease
* History of chronic immunodeficiency or chronic viral infections such as Epstein Barr virus, hepatitis or HIV
* Currently undergoing treatment for cancer
* Current treatment with immuno-suppressant drugs
* Pregnancy

Primary outcomes:
measure: Number of healthy participants enrolled
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Manhasset
country: United States
facility: The Feinstein Institute for Medical Research
state: New York
Study officials:
affiliation: Northwell Health
name: Peter Gregersen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01549756: Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers
Official title: Qualitative Research for Stage 4 Stomach Cancer and Their Caregivers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Stage 4 Stomach/Gastric Cancer
Patients and Caregivers
Keywords: stage 4 stomach cancer
stage 4 gastric cancer
Lead sponsor: Find A Cure Panel
Sponsor class: OTHER
First posted: 2012-03-09
Enrollment: 30
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: stage 4 stomach cancer patients and caregivers

Brief summary: Find A Cure Panel is looking for people with Stage 4 stomach/gastric cancer or the caregivers of people with Stage 4 stomach/gastric cancer to participate in anonymous and qualitative research that will take an estimated 60 minutes of your time.

This is opinion based, experiential research and is NOT a drug trial.

Note that Stage IV is also known as "advance disease" or metastatic stomach/gastric cancer.

If you are interested in participating, please email FACP at: info@findacurepanel.com


Eligibility criteria: Inclusion Criteria:stage 4 stomach cancer patients and caregivers -

Exclusion Criteria:loved one must still be living

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: Sample Czar
state: California
Study officials:
References:
Clinical trial NCT05748756: Bone Marrow Aspirate Concentrate in Treating Mandibular Cystic Defects
Official title: The Effect of Bone Marrow Aspirate Concentrate in the Treatment of Mandibular Cystic Defects (Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mandible Cyst
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Mandibular cystic defect healing is a complex process. Various methods have been developed to shorten the bone regeneration time and improve its quality. Autogenous grafting is the gold standard for filling cystic defects due to the osteogenesis property provided by the viable cells but is related to donor site morbidity. Allografts and Xenografts are used for the same purpose. However, the increased cost is their main disadvantage. Bone marrow aspirate concentrate is now used to enhance the healing and regeneration process in many areas of the body with no morbidity and low cost.


Eligibility criteria: Inclusion Criteria:

* Patients suffering from mandibular cystic defect.
* Cystic defect width of 4-8 cm that requires removal under general anesthesia.

Exclusion Criteria:

* Medically compromised patients contradicting operation.
* Previously enucleated lesions.
* Previous surgery, tumor, infection to the pelvis affecting the anterior iliac crest.
* Infected Cysts

Primary outcomes:
measure: Change in pain scores
timeFrame: 1st day, 1 week, 4 weeks, 6 weeks
measure: Change in bone density
timeFrame: at baseline, 3 months, 6 months
Secondary outcomes:
measure: change in wound dehiscence
timeFrame: 1st day, 1 week, 4 weeks, 6 weeks
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt
state: Azarita
Study officials:
References: